“
TL;DR
The analysis included 898 patients with complete data, among whom 188 were diagnosed with cancer cachexia.
Journal of Cachexia, Sarcopenia and Muscle · 9 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The analysis included 898 patients with complete data, among whom 188 were diagnosed with cancer cachexia.
The analysis included 898 patients with complete data, among whom 188 were diagnosed with cancer cachexia. 28.07%, P<0.001) compared to the low TA group. The findings suggest TA is a clinically useful and cost-effective prognostic tool for LAGC patients with cancer cachexia. Limitations include the focus on a single cancer type and the need for further validation across diverse cancer types and treatments.